BofA downgraded Erasca to Neutral from Buy with a price target of $6, down from $11.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ERAS:
- Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Erasca receives FDA Fast Track Designation for naporafenib
- Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
- Erasca price target lowered to $8 from $10 at H.C. Wainwright
- Erasca achieves key milestones for naporafenib, ERAS-801